Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nina Vibeche Skei"'
Autor:
Jan Kristian Damås, Tom Ivar Lund Nilsen, Stian Lydersen, Erik Solligård, Lise Tuset Gustad, Hallie Prescott, Nina Vibeche Skei, Siri Tandberg Knoop, Randi Marie Mohus, Alen Brkic, Kristin Vardheim Liyanarachi
Publikováno v:
BMJ Open, Vol 13, Iss 8 (2023)
Objectives To estimate temporal trends in incidence rate (IR) and case fatality during a 14-year period from 2008 to 2021, and to assess possible shifts in these trends during the COVID-19 pandemic.Setting All Norwegian hospitals 2008–2021.Particip
Externí odkaz:
https://doaj.org/article/f9cc643218e54e14a6f016c8669dfa69
Autor:
Nina Vibeche Skei, Tom Ivar Lund Nilsen, Siri Tandberg Knoop, Hallie C. Prescott, Stian Lydersen, Randi Marie Mohus, Alen Brkic, Kristin Vardheim Liyanarachi, Erik Solligård, Jan Kristian Damås, Lise Tuset Gustad
ImportanceSepsis is one of the leading causes of morbidity and mortality. The majority of sepsis cases is attributed to bacterial infections, but virus infections can also induce sepsis. Conflicting results in incidence rates and case fatality trends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1f4b06520bf28385b83e9538b814ac0
https://doi.org/10.1101/2022.11.18.22282501
https://doi.org/10.1101/2022.11.18.22282501
Autor:
Andreas Barratt-Due, Asgeir Johannessen, Lars Thoresen, Pål Aukrust, Bente Halvorsen, Birgitte Stiksrud, Katerina Nezvalova Henriksen, Beate Vestad, Trine Kåsine, Reidar Kvåle, Anders Benjamin Kildal, Roy Bjørkholt Olsen, Johannes R. Hov, Tori Vigeland Lerum, Marius Trøseid, Thor Ueland, Trine Ranheim, Mette Haugli, Tove Lekva, Åse Berg, Annika E. Michelsen, Hilde Skudal, Ragnhild Eiken, Ravinea Manotheepan, Anne Ma Dyrhol-Riise, Carl Magnus Ystrøm, Inge C. Olsen, Hedda Hoel, Anders Tveita, Kristian Tonby, Kristian Holm, Tuva B. Dahl, Raisa Hannula, Bård Reiakvam Kittang, Ole Henning Skjønsberg, Saad Aballi, Nina Vibeche Skei
ObjectiveAlthough COVID-19 is primarily a respiratory infection, mounting evidence suggests that the GI tract is involved in the disease, with gut barrier dysfunction and gut microbiota alterations being related to disease severity. Whether these alt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::392ae3b6b3abd158d7cf543ac73f5249
https://doi.org/10.1101/2021.07.13.21260412
https://doi.org/10.1101/2021.07.13.21260412
Autor:
Asgeir Johannessen, Hedda Hoel, Roy Bjørkholt Olsen, Karoline Hansen Skåra, Aleksander Rygh Holten, Anne Ma Dyrhol-Riise, Anders Benjamin Kildal, Carl Magnus Ystrøm, Fridtjof Lund-Johansen, Alexander Mathiessen, Trine Kåsine, Susanne Gjeruldsen Dudman, Cathrine Fladeby, Nina Vibeche Skei, Birgitte Tholin, Åse Berg, Trung Tran, Gernot Ernst, Anne Steffensen, Saad Aballi, Ane-Kristine Finbråten, Inge C. Olsen, Pål Aukrust, Olav Dalgard, Jan Terje Andersen, Bård Reiakvam Kittang, Lars Heggelund, Anders Tveita, Bjørn Blomberg, Marius Trøseid, Tuva B. Dahl, Mette Haugli, Kristian Tonby, Ragnhild Eiken, Lan Ai Kieu Le, Raisa Hannula, Fredrik Müller, Dag Arne Lihaug Hoff, Lars Thoresen, Hilde Skudal, Andreas Barratt-Due, Pawel Mielnik, Katerina Nezvalova-Henriksen
Publikováno v:
Annals of internal medicine
Annals of Internal Medicine
Annals of Internal Medicine
BACKGROUND: New treatment modalities are urgently needed for patients with COVID-19. The World Health Organization (WHO) Solidarity trial showed no effect of remdesivir or hydroxychloroquine (HCQ) on mortality, but the antiviral effects of these drug